argenx reports positive phase 3 ADAPT SERON results of VYVGART in AChR-Ab seronegative gMG
VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications
VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications
As part of its partnership with Dr. Reddy’s Laboratories (DRL), FDA acceptance also triggers a $4.2 million milestone payment to Coya
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
Subscribe To Our Newsletter & Stay Updated